abstract: Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias British Columbia, Canada

Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias.:

Diabetologia. 2011 Sep;54(9):2263-71

Abstract

AIMS/HYPOTHESIS:
Despite the vast body of epidemiological literature on the risk of cancer in people with diabetes, few studies have examined the pattern of cancer risk during different time windows following diabetes onset. The objective of the study was to examine the risks of site-specific cancer in people with incident type 2 diabetes during different time windows following diabetes onset.

METHODS: 

This was a population-based retrospective cohort study. The study period was 1 April 1994 to 31 March 2006; censoring occurred at 31 March 2006, at death or on departure from British Columbia, Canada. Using linked health databases, we identified incident cohorts with and without diabetes, who were matched by age, sex and index year. Following a minimum 2-year cancer washout period, first site-specific cancers were identified prospectively in both cohorts.

RESULTS: 

Within 3 months following diabetes onset, participants with diabetes had significantly increased risks of colorectal, lung, liver, cervical, endometrial, ovarian, pancreatic and prostate cancers. After the initial 3-month period, the risks for colorectal (HR 1.15, 95% CI 1.05, 1.25), liver (HR 2.53, 95% CI 1.93, 3.31) and endometrial (HR 1.58, 95% CI 1.28, 1.94) cancers remained significantly elevated compared with those without diabetes.

The diabetes cohort remained at increased risk of pancreatic cancer in later years, but followed a different pattern: HR 3.71 at 3 months-1 year, 2.94 at 1-2 years, 1.78 at 2-3 years and 1.65 at 3-10 years (p value for all <0.01). After an initial period of elevated risk, men with type 2 diabetes subsequently had a decreased risk of prostate cancer (HR 0.82, 95% CI 0.76, 0.88).

CONCLUSIONS/INTERPRETATION: 

People with type 2 diabetes are at increased risk of select cancers; this risk is particularly elevated at the time of diabetes onset, which is likely to be due to increased ascertainment.

Can a Facebook status do anything to fight cancer? - The Globe and Mail (plus commentaries)

Marjie - The support of 'family'

"...Margie is in the midst of a battle with colon, ovarian, and uterus cancer, and Saturday was her first time attending...."

Endometriosis related to family history of malignancies in the Yale series

Conclusions:
"These data suggest a familial association of endometriosis with ovarian, colon and prostate cancers. This evidence could support the genetics and molecular similarities between endometriosis javascript:void(0)and cancer. Future studies will be important to determine a clear genetic link between endometriosis and cancer."

Patient with Eight Metachronous Gastrointestinal Cancers Thought to be Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Lynch Syndrome.

short abstract

Use of CT Scans Linked to Cancer Risk, Studies Say | netReturns | e-Newsletter

"There is considerable disagreement in the scientific community about the validity of these models," notes Rosaleen Parsons, M.D., chair of the department of diagnostic imaging at Fox Chase Cancer Center. "And some scientists believe the radiation dose from these CT scans may not lead to any increased risk of cancer."

In the second study, conducted at the University of California-San Francisco, researchers compared CT scan use at four San Francisco Bay area facilities. They found that the amount of radiation from a CT scan may be up to four times greater than estimated in previous studies. In addition, they noted significant differences among different institutions and, in some instances, within the same institution, when looking at the radiation dose associated with CT scans.

full free access: TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use — Cold Spring Harbor Perspectives in Biology

Somatic TP53 mutations occur in almost every type of cancer at rates from 38%–50% in ovarian and..........TP53 mutations, but not p53 positive immunohistochemistry (IHC), have been consistently associated with poor prognosis in cancers such as breast, colorectal, head and neck, and leukemia.....In terms of clinical applications, TP53 mutations have proven to be extremely complex biomarkers. Despite impressive progress in mechanistic understanding of p53 structure and function, p53 research has not yet generated applications of wide impact on cancer management and therapy."